• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Spectral AI Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    6/3/25 4:01:21 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care
    Get the next $MDAI alert in real time by email
    false 0001833498 0001833498 2025-05-29 2025-05-29 0001833498 MDAI:CommonStockParValue0.0001PerShareMember 2025-05-29 2025-05-29 0001833498 MDAI:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember 2025-05-29 2025-05-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(D) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): May 29, 2025

     

    SPECTRAL AI, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40058   85-3987148
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    2515 McKinney Avenue, Suite 1000

    Dallas, Texas

      75201
    (Address of principal executive offices)   (Zip Code)

     

    (972) 499-4934

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbols   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   MDAI   The Nasdaq Stock Market LLC
    Redeemable Warrants, each whole warrant exercisable for one share of Common Stock, at an exercise price of $2.75 per share   MDAIW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 4.01 Changes in Registrant’s Certifying Accountant

     

    (a)

    On May 29, 2025, Spectral AI, Inc. (the “Company”) dismissed KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm, effective immediately. The Company’s Audit Committee unanimously voted in favor of dismissing KPMG as the Company’s independent auditors. The Company’s Board of Directors (the “Board”) ratified such recommendation.

     

    KPMG has served as the Company’s independent registered public accounting firm since 2021.

     

    The audit reports of KPMG on the Company’s financial statements as of and for the two most recent fiscal years ended December 31, 2024 and December 31, 2023, did not contain an adverse opinion or a disclaimer of opinion, nor were such reports qualified or modified as to uncertainties, audit scope or accounting principles.

     

    During the Company’s two most recent fiscal years ended December 31, 2024 and 2023 and the subsequent interim period through May 29, 2025, there were no: (1) disagreements, within the meaning of Item 304(a)(1)(iv) of Regulation S-K promulgated under the Exchange Act (“Regulation S-K”) and the related instructions thereto, with KPMG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of KPMG, would have caused KPMG to make reference to the subject matter of the disagreements in connection with their audit reports, or (2) reportable events within the meaning of Item 304(a)(1)(v) of Regulation S-K and the related instructions thereto, except that KPMG communicated the material weaknesses in the Company’s internal control over financial reporting as previously reported by the Company in Part II, Item 9A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, with respect to financial close process controls which relate to all financial statement accounts not consistently operating effectively or lacking appropriate evidence to ensure that account reconciliations, transactions, and journal entries were performed or reviewed at the appropriate level of precision and on a timely basis, and in Part II, Item 9A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 with respect to (a) lack of communication within management and internal departments regarding complex and unusual arrangements, (b) a lack of adequately designed controls to ensure the proper recording of operating expenses, related accruals and unbilled revenue in the correct period, and (c) financial close process controls which relate to all financial statement accounts not consistently operating effectively or lacking appropriate evidence to ensure that account reconciliations, transactions, and journal entries were performed or reviewed at the appropriate level of precision and on a timely basis. These reportable events were discussed among the Audit Committee and KPMG. KPMG has been authorized by the Company to respond fully to the inquiries of Forvis Mazars Group (“Forvis”), the successor independent registered public accounting firm, concerning these reportable events.

     

    The Company has provided KPMG with the disclosures under this Item 4.01 and has requested KPMG to furnish the Company with a letter addressed to the Securities and Exchange Commission (the “SEC”) stating whether it agrees with the statements made by the Company in this Item 4.01 and, if not, stating the respects in which it does not agree. The letter from KPMG is filed as Exhibit 16.1 to this Current Report on Form 8-K.

     

    1

     

     

    (b)

     

    On May 29, 2025, upon the recommendation of the Audit Committee of the Board and the Board, the Company approved the engagement of Forvis as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025. During the Company’s two most recent fiscal years (ended December 31, 2024 and December 31, 2023) and the subsequent interim period prior to the engagement of Forvis, neither the Company, nor anyone on the Company’s behalf consulted with Forvis regarding (1) the application of accounting principles to a specified transaction, either completed or proposed; (2) the type of audit opinion that might be rendered on the Company’s financial statements; or (3) the subject of any “disagreement,” as defined in Item 304(a)(1)(iv) of Regulation S-K under the Exchange Act and the instructions thereto, or a “reportable event,” as defined in Item 304(a) (1)(v) of Regulation S-K under the Exchange Act.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit
    No.
      Description
    16.1   Letter from KPMG LLP, dated June 2, 2025
    104   Cover Page Interactive Data File (formatted as Inline XBRL).

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: June 3, 2025

     

      SPECTRAL AI, INC.
       
      By: /s/ Vincent S. Capone
      Name:  Vincent S. Capone
      Title: Chief Financial Officer

     

     

    3

     

     

    Get the next $MDAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDAI

    DatePrice TargetRatingAnalyst
    1/23/2024$4.00Buy
    BTIG Research
    More analyst ratings

    $MDAI
    SEC Filings

    See more
    • Spectral AI Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Spectral AI, Inc. (0001833498) (Filer)

      6/3/25 4:01:21 PM ET
      $MDAI
      Medical/Dental Instruments
      Health Care
    • Spectral AI Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Spectral AI, Inc. (0001833498) (Filer)

      5/30/25 4:00:32 PM ET
      $MDAI
      Medical/Dental Instruments
      Health Care
    • Spectral AI Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Spectral AI, Inc. (0001833498) (Filer)

      5/29/25 4:00:35 PM ET
      $MDAI
      Medical/Dental Instruments
      Health Care

    $MDAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Spectral AI with a new price target

      BTIG Research initiated coverage of Spectral AI with a rating of Buy and set a new price target of $4.00

      1/23/24 7:24:00 AM ET
      $MDAI
      Medical/Dental Instruments
      Health Care

    $MDAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mellish Martin C.B. was granted 5,000 shares, increasing direct ownership by 26% to 24,398 units (SEC Form 4)

      4 - Spectral AI, Inc. (0001833498) (Issuer)

      6/6/25 4:00:24 PM ET
      $MDAI
      Medical/Dental Instruments
      Health Care
    • Director Cotton Richard John was granted 9,699 shares, increasing direct ownership by 17% to 66,927 units (SEC Form 4)

      4 - Spectral AI, Inc. (0001833498) (Issuer)

      5/1/25 4:00:30 PM ET
      $MDAI
      Medical/Dental Instruments
      Health Care
    • Director Mellish Martin C.B. was granted 9,699 shares, increasing direct ownership by 100% to 19,398 units (SEC Form 4)

      4 - Spectral AI, Inc. (0001833498) (Issuer)

      4/30/25 5:02:54 PM ET
      $MDAI
      Medical/Dental Instruments
      Health Care

    $MDAI
    Leadership Updates

    Live Leadership Updates

    See more
    • Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer

      DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Stanley Micek has been named the Company's Chief Operating Officer ("COO"). Micek's promotion reflects his role change from Interim COO of the Company since May, 2024 "Stan has demonstrated exceptional leadership, operational insight, and a deep understanding of our business during his time as interim COO," said Dr. J. Michael DiMaio, M.D., Chairman of the Company's Board of Directors. "His efforts leading our Research and Devel

      5/30/25 8:00:00 AM ET
      $MDAI
      Medical/Dental Instruments
      Health Care
    • Spectral AI Announces Voting Results from 2025 Annual Meeting of Stockholders

      DALLAS, May 29, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announced results from its 2025 Annual Meeting of Stockholders held earlier today. A total of 15,551,068 shares representing 60.8% of the Company's total shares outstanding were represented at the meeting, either in person or by proxy. Both of the proposals set forth by the Company were approved by its stockholders. The voting results are detailed below. Six directors were elected to serve on the Company's Board of Directors until the next Annual Me

      5/29/25 8:00:00 AM ET
      $MDAI
      Medical/Dental Instruments
      Health Care
    • Spectral AI Set to Join Russell Microcap® Index

      DALLAS, May 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective following the closing of US equity markets on Friday, June 28, 2024 according to a preliminary list of additions posted Friday, May 24, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, 2024 ranking them by total market capitalization. Members

      5/29/24 8:31:22 AM ET
      $MDAI
      Medical/Dental Instruments
      Health Care

    $MDAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $MDAI
    Financials

    Live finance-specific insights

    See more

    $MDAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $MDAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Spectral AI Inc.

      SC 13G/A - Spectral AI, Inc. (0001833498) (Subject)

      11/14/24 4:09:49 PM ET
      $MDAI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Spectral AI Inc. (Amendment)

      SC 13G/A - Spectral AI, Inc. (0001833498) (Subject)

      4/19/24 6:49:51 PM ET
      $MDAI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Spectral AI Inc. (Amendment)

      SC 13D/A - Spectral AI, Inc. (0001833498) (Subject)

      2/27/24 2:07:28 PM ET
      $MDAI
      Medical/Dental Instruments
      Health Care
    • Spectral AI Announces 2025 First Quarter Financial Results

      Q1 Overview Research & Development Revenue of $6.7 MillionImproved Capital Structure Reflected in Cash of $14.1 MillionContinued work on planned De Novo submission to the FDA in the first half of 2025 DALLAS, May 13, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2025 and provided an update on its ongoing business activities. "During the first quarter we continued to execute against our strategic plan and are working hard towards our De Nov

      5/13/25 4:05:00 PM ET
      $MDAI
      Medical/Dental Instruments
      Health Care
    • Spectral AI Schedules 2025 First Quarter Financial Results and Conference Call

      DALLAS, May 02, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential today announced that it will report financial results for the first quarter ended March 31, 2025 on Tuesday, May 13, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results. Investors interested in participating in the live call can dial: 833-630-1956 - U.S.412-317-1837 - International A simultaneous webcast of the call may be accessed online from the Events

      5/2/25 4:00:00 PM ET
      $MDAI
      Medical/Dental Instruments
      Health Care
    • Spectral AI Announces 2024 Fourth Quarter and Full Year Financial Results

      2024 Research & Development Revenue of $30 Million Successful Results from the US Burn Validation Study On Track for Regulatory Submission in US for DeepView™ System DALLAS, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence ("AI") company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter ("Q4 2024") and full year ("FY 2024") ended December 31, 2024, and provided an update on its ongoing business activities. "Spectral AI achieved much in 2024. Our top-l

      3/27/25 4:55:44 PM ET
      $MDAI
      Medical/Dental Instruments
      Health Care
    • Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer

      DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Stanley Micek has been named the Company's Chief Operating Officer ("COO"). Micek's promotion reflects his role change from Interim COO of the Company since May, 2024 "Stan has demonstrated exceptional leadership, operational insight, and a deep understanding of our business during his time as interim COO," said Dr. J. Michael DiMaio, M.D., Chairman of the Company's Board of Directors. "His efforts leading our Research and Devel

      5/30/25 8:00:00 AM ET
      $MDAI
      Medical/Dental Instruments
      Health Care
    • Spectral AI Announces Voting Results from 2025 Annual Meeting of Stockholders

      DALLAS, May 29, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announced results from its 2025 Annual Meeting of Stockholders held earlier today. A total of 15,551,068 shares representing 60.8% of the Company's total shares outstanding were represented at the meeting, either in person or by proxy. Both of the proposals set forth by the Company were approved by its stockholders. The voting results are detailed below. Six directors were elected to serve on the Company's Board of Directors until the next Annual Me

      5/29/25 8:00:00 AM ET
      $MDAI
      Medical/Dental Instruments
      Health Care
    • Spectral AI Research Partner Using DeepView System Wins Best Research Project at the 2025 Education Awards

      DALLAS, May 20, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential today announced that its research partners, RCSI Skin Wounds and Trauma (SWaT) Research Center and RCSI Connolly Hospital, have been awarded Best Research Project at the 2025 Education Awards utilizing the DeepView System for their Diabetic Foot Ulcers (DFUs) project. The Education Awards recognize, encourage and celebrate excellence in third-level education across Ireland, including both state-funded and private institutions. The awards are par

      5/20/25 8:00:00 AM ET
      $MDAI
      Medical/Dental Instruments
      Health Care
    • Dimaio John Michael bought $10,320 worth of shares (6,000 units at $1.72), increasing direct ownership by 0.40% to 2,491,908 units (SEC Form 4)

      4 - Spectral AI, Inc. (0001833498) (Issuer)

      5/14/24 11:17:43 AM ET
      $MDAI
      Medical/Dental Instruments
      Health Care